 By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Update on Phase 3 DISRUPT Trial In January, 2020, ContraFect Corp. NASDAQ:CFRX announced the first patient had been dosed in the Phase 3 DISRUPT Direct Lysis of Staph aureus Resistant Pathogen Trial study of exebacase in patients with Staphylococcus aureus bacteremia, including right-sided endocarditis 